ElmediX

ElmediX was founded in 2015 as a spin-off company of the University of Antwerp with the goal to significantly increase the progression-free survival of advanced pancreatic cancer patients with high quality-of-life.

There is a large unmet medical need with over 495.000 new pancreas cancer patients per year and 91% mortality rate. The overall survival of pancreatic cancer did not change much in the last 40 years. Co-founders Professor dr. John-Paul Bogers (CEO) and Ir. Johan Van den Bossche (President of the Board of Directors) gathered a team of multidisciplinary experts to adress this challenge.

By developing the first medical device (TempoCure®) able to maintain whole-body temerature within a safe and effective temperature window for long periods of time, ElmediX wants to bring the concept of full-body thermal therapy towards cancer treatment. Preclinal evidence of safety and preliminary efficacy on in vitro, in vivo and mammalian animal models has been achieved in recent years. Thermal therapy has proven in multiple clinical trials to be a valid treatment to shrink tumors and extend survival with enhanced quality of life.

With 8 patent families protecting the ElmediX' technology, ElmediX has established a strong IP position around the world (EU, USA, China and Hong Kong).

In October 2020 the First-In-Human clinical trial started at UZA and is ongoing. ElmediX aims to finish clinical trials and to obtain regulatory approval by mid 2025.